Comparative Study of the Protective Effects of Taurine and Melatonin on Cytochrome P450 2E1 and some Oxidative Stress Markers in Streptozotocin-induced Diabetic Rats

Manal El-Batch, Azza M. Hassan*, Heba A. Mahmoud**
Medical Biochemistry, Microbiology & Immunology* and Pharmacology** Departments, Faculty of Medicine, Tanta University

ABSTRACT

Melatonin and taurine have alleviative effects in streptozotocin (STZ)-induced diabetic rats. Male Wistar rats were divided into non-diabetic, diabetic, diabetic melatonin (administered at 200 µg/kg/day dissolved in 0.5 ml of normal saline) and diabetic taurine (administered at 2% in the drinking water) supplemented groups. At the end of the study, blood was collected and used for determination of glucose, total cholesterol, triglyceride levels, liver enzymes (ALT and AST), β-hydroxybutyrate (β-HB), in addition to advanced oxidation protein product (AOPP) level, and paraoxonase (PON1) enzyme activity. Also, liver tissue was examined for malondialdhyde (MDA) level, glutathione peroxidase (GPx) enzyme activity and cytochrome P450 2E1 (CYP2E1) both enzyme activity and gene expression. Light microscopy pictures of liver tissue were also evaluated for signs of its damage. An increased CYP2E1 activity and gene expression with a concomitant significant change in oxidative stress parameters were found in STZ-induced diabetic rats, suggesting the possible diabetes-induced injury. Taurine or melatonin supplementation to the diabetic rats alleviated these experimental parameters with more significant effect for taurine than that of melatonin. Suppression of β-HB production by taurine can be one of the mechanisms of reduction in CYP2E1. Conclusion: Taurine has the capabilities more than melatonin in protecting the liver from the hepatic injury induced by type 1 diabetes, by reducing the oxidative stress and restoring CYP2E1 activity and gene expression, suggesting hepatic protective nature of taurine in diabetic rats. Therefore antioxidants might prove beneficial as an adjuvant treatment to insulin in type 1 diabetes associated with manifestations of liver injury.

INTRODUCTION

Oxidative stress is involved in the etiology and pathogenesis of many diabetic complications. Streptozotocin (STZ) injection in animals generates type 1 diabetes and produces various kinds of reactive oxygen species (ROS) that are either formed by STZ itself over the short term or resulted from the induced hyperglycemia. The increased oxidative stress, as measured by indices of elevated lipid peroxidation, oxidative modification products of proteins, depletion of
endogenous antioxidant, and antioxidant enzyme activities in plasma and tissues, are commonly found in STZ-induced diabetic rats, and these alterations may cause tissues to be more susceptible to oxidative damage. The vulnerability of each tissue to oxidative stress can vary depending upon their expressed antioxidant enzymes. (3)

Liver is the focal organ of oxidative and detoxifying processes, as well as free radical reactions and the biomarkers of oxidative stress are elevated in the liver at an early stage in many diseases, including diabetes mellitus. (4)

Cytochrome P450 2E1 (CYP2E1) has been implicated in the generation of tissue damaging hydroxyl radicals in patients suffering from diabetes and liver diseases. (5,6) Therefore, any agent with inhibitory effect on CYP2E1 activity may be able to alleviate such oxidative stress effects.

Several studies have recently dealt with either maintenance of antioxidant defense of diabetic liver or reduction of peroxidative stress induced hepatic damage in experimental models. (7,8) Hence, it is recommended that therapy with antioxidants may signify a useful pharmacologic overture to the management of diabetes complications.

The antioxidant role of taurine (2-aminoethanesulfonic acid) has been attributed to its ability to scavenge ROS, to reduce the production of lipid peroxidation end products, and to stabilize biomembranes. (9) Melatonin (N-acetyl-5-methoxytryptamine), a secretory product of the pineal gland, is a potent scavenger of hydroxyl and peroxyl radical that regulates the activity of anti-oxidant enzymes. Melatonin ameliorated carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress and proinflammatory cytokines production. (10)

So, the aim of the present study was to compare between the effect of either taurine or melatonin on CYP2E1 activity, expression and some oxidative stress parameters in STZ-induced diabetes in rats, in order to elucidate their possible mechanisms on reducing hepatic insult in type 1 diabetes.

MATERIALS & METHODS

1. Chemicals

Bio-chemicals and substrates were purchased from Sigma–Aldrich chemicals (St. Louis, MO). STZ (Trade name Zanosar) was in the form of 1 g vials. The treatment dose of taurine and melatonin was chosen according to Yao et al., (11) and Montilla et al., (12) respectively.

2. Animals

2.1. Experimental animals and diets

Forty male Wistar rats weighing approximately between 150 and 170 g were acclimatized under laboratory condition for 2 weeks prior to the experiments. They were maintained under standard conditions of temperature (23±2 °C) with an alternating 12 h light/dark cycles and were allowed free access to food and water all times.

2.2. Induction of diabetes

Induction of diabetes was made by a single intraperitoneal injection of STZ at a dose of 70 mg/kg body
weight in freshly prepared ice-cold citrate buffer (0.1 M pH 4.0) for 3 consecutive days. STZ used to induce damage to pancreatic beta cells, exhibited massive glycosuria and hyperglycemia within 3 days. Diabetes was defined as a blood glucose level greater than 250 mg/dl [5] using a drop of blood obtained by a tail-vein puncture monitored at different time intervals throughout the study using ACCUTREND reagent strips (Roche Diagnostics GmbH, Germany).

2.3. Animal treatment
- After induction of diabetic state (within 72 hours after STZ injection), diabetic rats were divided into three groups with 10 rats in each group. One group was maintained on a standard diet (untreated-diabetes group; G-II), another one was injected by melatonin daily intraperitoneally three days prior to induction of diabetes in a dose of 200 µg/kg/day dissolved in 0.5 ml of normal saline (melatonin -diabetic treated group; G-III), and the last group treated with 2% (w/v) taurine in the drinking water which was made fresh daily (taurine -diabetic treated; G-IV), in addition to 10 rats received an intraperitoneal injection of a single dose of 0.1 mol/L sodium citrate buffer (pH 4.5) (normal control group; G-I)
- The body weight, food, and water intake were monitored daily throughout the study period (4 weeks). Dead rats were excluded from the study.
- At the end of the experiment, after an overnight fast, the rats were decapitated then:
  - The blood was collected partly in plain tube to obtain serum and partly on K3EDTA (tri-potassium ethylene diaminetetraacetic acid) coated tubes to obtain plasma, centrifuged at 3000 rpm for 20 min at 4°C, and used for determination of some biochemical analysis, mentioned later on
  - The liver excised, washed with ice cold saline to remove extraneous materials, cut into four parts and used as follow:

3. Liver homogenates

Preparation of liver tissue homogenates
- First part of the liver (3 g) minced and homogenized (potter-Elvenhjem tissue homogenizer) in 10 mM potassium phosphate containing 1 mM EDTA, pH 7.4, and centrifuged at 12,000 x g for 30 min at 4 °C. The resultant supernatant (free of insoluble materials), was collected, stored at -80 °C and used for determination of malondialdehyde (MDA) level, glutathione peroxidase (GPx) enzyme activity and protein content.
- Second part of the liver was used for microsomes preparation as described elsewhere [13]. It was homogenized in 4 vol.(w/v) of a 20 mM Tris /HCl, 150 mM KCl and 1 mM EDTA solution (pH 7.6), with a Teflon pestle (Potter-Elvehjem, Inframo, Wayne, NJ), and centrifuged at 9000 x g for 20 min. The post-mitochondrial supernatant obtained was centrifuged at 105 000 x g for 60 min. The pellet obtained was re-
suspended in a 20 mM Tris /HCl, 150 mM KCl and 3 mM MgCl₂ solution (pH 7.6) and centrifuged again at 105 000 x g for 60 min to obtain the final microsomal fraction. The microsomes were finally re-suspended in the Tris/HCl/KCl/MgCl₂ solution, containing 15% (v/v) glycerol in water (pH 7.6), immediately stored at -70 °C until used for determination of CYP2E1 activity. Centrifugation was performed using TL-100 Beckmann ultracentrifuge.

- Third part of the liver was used for determination of CYP2E1 expression as mentioned below.
- Fourth part was used for histopathological examination.

4. Biochemical analysis

4.1 Fasting plasma glucose level:
It was determined by glucose oxidase method using a commercial kit (Elitech Diagnostics Company, France) according to the manufacturer instructions.

4.1.2 Total serum cholesterol and triglyceride levels:
They were estimated using the appropriate kits (Boehringer Mannheim, Germany).

4.1.3 Serum ALT and AST activities:
They were measured using Randox kits according to manufacturer instructions.

4.1.4 Plasma β-HB concentration:
It was determined using the kits purchased from Randox Laboratories (Antrum, UK) according to McGarry et al. (14)

4.1.5 Plasma AOPP level:
It was determined according to Witko-Sarsat et al. (15) Briefly, AOPP were measured by spectrophotometry on a microplate reader and were calibrated with chloramine-T (Sigma, St. Louis, MO) solutions that in the presence of potassium iodide absorb at 340 nm. In test wells, 200 µl of plasma diluted 1/5 in phosphate buffer saline (PBS) was placed on a 96-well microtiter plate, and 20 µl of acetic acid was added. In standard wells, 10 µl of 1.16 M potassium iodide (Sigma) was added to 200 µl of chloramine-T solution (0–100 µmol/liter) followed by 20 µl of acetic acid. The absorbance of the reaction mixture is immediately read at 340 nm on the microplate reader against a blank containing 200 µl of PBS, 10 µl of potassium iodide, and 20 µl of acetic acid. AOPP concentrations were expressed as micromoles per liter of chloramine-T equivalents (μmol/l).

4.1.6 Serum PON1 enzyme activity:
It was measured by adding serum to Tris buffer (100 mmol/L, pH 8.0) containing 2 mmol/L CaCl₂ and 1 mmol/L paraoxon (O,O-diethyl-O-nitrophenylphosphate). The rate of generation of P-nitrophenol was determined at 405 nm, 25 °C with the use of Ultro spec 1000 (Pharmacia Biotech) spectrophotometer as described previously. (16)

4.1.7 Liver tissue malondialdehyde (MDA):
It was measured according to Halliwell & Chirico, (17) that depends on that MDA reacts with thiobarbituric acid (TBA) producing thiobarbituric acid reactive substance (TBARS), a pink chromogen, which can be measured spectrophotometrically at 532 nm. MDA expressed as nmol/g tissue and
was calculated using $1.65 \times 10^5 \text{M}^{-1} \text{cm}^{-1}$ as molar absorption coefficient.

4.1.8 Liver tissue GPx activity:

It was measured according to Flohe and Gunzler (18) based on the coupling reaction with glutathione reductase (GR). The oxidized glutathione (GSSG) formed after reduction of hydroperoxide by GPx is recycled to its reduced state by GR in the presence of NADPH. The oxidation of NADPH is accompanied by a decrease in absorbance at 340 nm. One unit of GPx was defined as the amount of enzyme that catalyzes the oxidation of 1 nmol of NADPH per minute at 25 ºC. The enzyme activity was calculated using a molar extinction coefficient for NADPH of 6.220 M$^{-1}$ cm$^{-1}$ and normalized to protein concentration and it was expressed as nanomoles of NADPH consumed per minute per milligram of protein.

4.1.9 Hepatic microsomal CYP2E1 activity:

It was estimated spectrophotometrically by measuring the hydroxylation of p-nitrophenol to produce p-nitrocatechol according to Reinke and Moyer (19). Briefly, 200µl microsomes (equivalent to 1-2 mg protein) were mixed with 0.2 mM p-nitrophenol, 50 mM Tris- HCl and 5 mM MgCl2 (pH 7.4). The reaction was performed at 37 ºC and was started by the addition of 1 mM NADPH. After 10 min, the reaction was stopped with 0.5 ml of 0.6 N perchloric acid. The precipitated proteins were removed by centrifugation at 3000 x g for 5 min, 1 ml of the supernatants was mixed with 100µl of 10 N NaOH and absorbance was read at 510 nm. An extinction coefficient of 9.53 M$^{-1}$ cm$^{-1}$ for p-nitrocatechol was used and the result was expressed as nanomoles of p-nitrocatechol formed/min/mg protein.

4.1.10 Protein content in tissue homogenate:

It was determined by the Lowry method using bovine serum albumin as a standard (20).

4. 2 Gene expression of cytochrome P450 2E1

4.2.1. Preparation of Total Liver RNA

Total RNA was prepared from liver tissue according to the manufacture instructions (Promega). Approximately 100-200 mg of liver tissue was homogenized and subjected to RNA extraction to disrupt cells followed by denaturation of nucleoprotein complexes, inactivation of endogenous ribonuclease (RNase) activity, and finally removal of proteins and DNA. The resulting RNA was reconstituted in diethylpyrocarbonate-treated water (DEPC-H$_2$O), checked for purity and integrity spectrophotometrically at 260 nm and by gel electrophoresis and used for RT-PCR.

4.2.2 RT-PCR for CYP2E1

Reverse transcription of 10 µg of RNA to a corresponding amount of cDNA was carried out according to the manufacture instructions (Promega, USA) and stored at -20º until use. Amplification of cDNA and the selection of the primer sequences were done according to Yang and Raner (21). The PCR reactions of cDNA were performed in a final volume of 50 µl consisting of 5 µl cDNA, 5 µl 10X PCR buffer, 200 µM of each deoxynucleotide triphosphate, 2.5 mM MgCl2, 1.5 U AmpliTaq DNA polymerase (Promega,USA) and 50
pmol each of the following CYP2E1 specific forward and reverse primers (Life technologies, USA): forward: 5'-TGCCATCAAGGATAGGCAAG-3'; reverse: 5'-AATGCTGCAAATGGCACAC-3'. PCR reactions were carried out in a Perkin-Elmer 9600 thermal cycler starting with heating at 95 ºC for 4 min then using melting, annealing, and extension cycling conditions of 94º for 1 min, 60 º for 1 min, and 72 º for 2 min respectively. All amplifications were carried out for 30 cycles followed by final extension time at 75 ºC for 4 min. All reactions were conducted with β-actin primers (790 bp) as internal controls (5'primer: 5'TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA 3', 3'primer: 3'CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG. 5', Stratagene).

An aliquot of 20 µl from each amplified cDNA product (356 bp) was separated on 2% agarose gel (Sigma), and visualized by UV light illuminator using ethidium bromide staining and photographed by Polaroid film. The intensity of bands was quantified by gel proanalyzer image analyzer version III where the area of a selected band was blotted against calibration curve of a single image using multiple standard bands to give the band amount in nanograms (ng) and the results were analyzed by this computer software (Biorad, UK) (Fig. 1).

**Statistical analysis**

All the values are expressed as mean ± SD. Statistical analyses were performed using Student "t" test for comparing two groups. When comparing more than 2 groups, one-way analysis of variance followed by Tukey's post hoc test (multiple comparisons) was performed. A spearman rank correlation was performed to determine the correlation between the studied parameters. A p-value < 0.05 was considered significant. SPSS version 10.0 was used for all statistical analysis.

**RESULTS**

**Body weight, plasma glucose levels, Lipid profile, hepatic enzyme activities and β-Hydroxybutyrate**

Table (1) summarizes the mean changes in body weights, plasma glucose levels, lipid profile, hepatic enzyme activities and β-HB in all the studied groups. Before the commencement of this study, all the groups had similar body weight, comparable levels of plasma glucose and lipid profiles (data not shown).

After STZ administration, rats demonstrated the typical characteristics of type 1 diabetes such as increase in food and water intake, polyuria (data not shown), the body weights were significantly decreased and the plasma glucose level as well as serum cholesterol, triglyceride concentrations were significantly increased in diabetic rats (G-II), when compared to control rats (G-I).

Administration of melatonin (G-III), or taurine (G-IV) significantly alleviated the hyperlipidemia, and restored the body weight slightly non-significantly as compared to G-I (but higher body weight than that of diabetes group (G-II)), but as regards plasma glucose, melatonin induce an insignificant changes, however taurine induce significant decrease in plasma glucose level as compared to G-II
with still significant differences with G-I. Of notice, STZ-induced diabetes caused an increase in the ALT, AST activities in the serum, and in plasma β-HB level. However, melatonin or taurine supplementation not only reduced the ALT and AST serum levels but also, significantly reduced plasma β-HB (with marked decrease in G-IV than in G-III). (Table 1)

**Oxidative stress**

Table 2 shows that plasma AOPP and liver MDA (oxidative stress markers), were significantly elevated in G-II compared with G-I. Melatonin or taurine decreased significantly their levels as compared with G-II, with no significant differences as compared with G-I, while serum PON1 and hepatic GPx were significantly decreased in G-II as compared with the control, melatonin or taurine caused significant increase in serum PON1 activities (with marked increase in G-IV), but only taurine treatment can elevate liver GPx to near normal, with no significant effect for melatonin.

**Catalytic activity and expression of CYP2E1**

In table (2) liver microsomes CYP2E1 activities in diabetic rats were significantly higher than those in non-diabetic rats. Taurine or melatonin supplementation in diabetic rats caused significant decrease in CYP2E1 activity in liver microsomes as compared with G-II with no significant differences for taurine supplementation, but still significant differences for melatonin supplementation when compared with the G-I.

A significant correlation exists not only between CYP2E1 activities and gene expression but also between both CYP2E1 activities and gene expression and the studied parameters. (Table 3)

The expression of CYP2E1 in different studied groups is represented in figure 1 and 2. Similar to the results of enzyme activity, there were significant differences between all the studied groups except between G-I and G-IV with (F =23.1, P<0.0001), in which hepatic CYP2E1 mRNA expression in untreated diabetic rats (22.9 ± 4.8 ng) was significantly increased (P<0.001) as compared to non-diabetic control (13.4±0.9 ng). Melatonin and taurine supplementation in diabetic rats caused significantly decreased in hepatic CYP2E1 mRNA (17.7± 2.3 ng vs. 14.2 ±1.8 ng, respectively) compared to levels in untreated diabetic rats but with more significant decrease (P<0.001) in taurine than in melatonin (Fig.2).  

**Histopathological pictures of the liver:** are presented in fig 3 from A to E
Table (1): comparison between the studied groups as regards body weight, fasting plasma glucose, lipid profile, hepatic enzyme activities and level of β-Hydroxybutyrate

<table>
<thead>
<tr>
<th>Parameter</th>
<th>G-I (n=10)</th>
<th>G-II (n=10)</th>
<th>G-III (n=10)</th>
<th>G-IV (n=10)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final body weight (g)</td>
<td>152.0±18</td>
<td>95.0±21</td>
<td>116.3±18.2</td>
<td>115.5±17</td>
<td>p&lt;0.001 All are sign except II vs. III, II vs. IV and III vs. IV</td>
</tr>
<tr>
<td>Final fasting plasma glucose level (mg/dl)</td>
<td>101.0±11</td>
<td>300.0±20</td>
<td>285.4±10.5</td>
<td>180.7±15.2</td>
<td>p&lt;0.001 All are sign except III vs. II,</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>123.2±19.7</td>
<td>145.8±15.8</td>
<td>122.6±21.1</td>
<td>118.8±17.9</td>
<td>p&lt;0.001 All are sign except III vs. IV and III vs. IV</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>79.4±12.8</td>
<td>122.7±24.8</td>
<td>92.7±14.9</td>
<td>82.3±6.1</td>
<td>p&lt;0.001 All are sign except III vs. IV and III vs. IV</td>
</tr>
<tr>
<td>ALT(U/l)</td>
<td>30±2</td>
<td>40±3</td>
<td>34±5</td>
<td>31±3</td>
<td>p&lt;0.001 All are sign except III vs. IV</td>
</tr>
<tr>
<td>AST(U/l)</td>
<td>35±3</td>
<td>50±4</td>
<td>39±4</td>
<td>38±3</td>
<td>p&lt;0.001 All are sign except III vs. IV and III vs. IV</td>
</tr>
<tr>
<td>β-Hydroxybutyrate (mmol/l)</td>
<td>0.7±0.2</td>
<td>4.5±0.3</td>
<td>2.9±0.3</td>
<td>1.8±0.4</td>
<td>p&lt;0.001 all groups are sign</td>
</tr>
</tbody>
</table>

Values are expressed as mean± SD, for ten animals in each group. G-I= control group  
G-II= untreated STZ induced diabetic group  
G-III= melatonin treated diabetic group  
G-IV= taurine treated diabetic group  
a Significantly different from the control group (p < 0.05). b Significantly different from the STZ treated group (p < 0.05).

Table (2): comparison between the studied groups as regards oxidative stress parameters and hepatic CYP2E1 activities

<table>
<thead>
<tr>
<th>Parameter</th>
<th>G-I (n=10)</th>
<th>G-II (n=10)</th>
<th>G-III (n=10)</th>
<th>G-IV (n=10)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma AOPP (μmol/l)</td>
<td>24.4±4.2</td>
<td>30.3±6.2</td>
<td>24.7±4.4</td>
<td>24.9±2.1</td>
<td>p&lt;0.01 All are sign except IV vs. III, I vs. IV and III vs. IV</td>
</tr>
<tr>
<td>Serum PON I activity (nmol/min/ml)</td>
<td>13.6±3.1</td>
<td>6.9±2.5</td>
<td>15.1±2.5</td>
<td>14.2±2.8</td>
<td>p&lt;0.001 All are sign except IV vs. III, I vs. IV and III vs. IV</td>
</tr>
<tr>
<td>Liver MDA (nmol/g. tissue)</td>
<td>23.6±3.1</td>
<td>31.6±5.5</td>
<td>24.3±3.8</td>
<td>23.9±2.8</td>
<td>p&lt;0.001 All are sign except IV vs. III, I vs. IV and III vs. IV</td>
</tr>
<tr>
<td>Liver GPx activity (nmol of NADPH oxidized/min/mg)</td>
<td>7.9±1.1</td>
<td>4.8±1.1</td>
<td>5.8±1.4</td>
<td>6.5±1.5</td>
<td>p&lt;0.001 All are sign except I vs. IV, and II vs. III and III vs. IV</td>
</tr>
<tr>
<td>Hepatic CYP2E1 activities (nmol/min/mg protein)</td>
<td>2.1±0.6</td>
<td>5.2±1.6</td>
<td>3.5±0.7</td>
<td>2.7±0.8</td>
<td>p&lt;0.001 All are sign except I vs. IV, and III vs. IV</td>
</tr>
</tbody>
</table>

Values are expressed as mean± SD, for ten animals in each group.  
G-I= control group  
G-II= untreated STZ induced diabetic group  
G-III= melatonin treated diabetic group  
G-IV= taurine treated diabetic group  
a Significantly different from the control group (p < 0.05). b Significantly different from the STZ treated group (p < 0.05).
Table (3): correlation between hepatic CYP2E1 activities, gene expression and other studied parameters in diabetic groups (n=30)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hepatic CYP2E1 activities (nmol/min/mg protein)</th>
<th>CYP2E1 gene expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Hydroxybutyrate (mmol/l)</td>
<td>0.49 &lt;0.001</td>
<td>0.50 &lt;0.001</td>
</tr>
<tr>
<td>Plasma AOPP (µmol/l)</td>
<td>0.37 &lt;0.05</td>
<td>0.40 &lt;0.05</td>
</tr>
<tr>
<td>Serum PON 1 activity (nmol/min/ml)</td>
<td>-0.40 &lt;0.05</td>
<td>0.43 &lt;0.05</td>
</tr>
<tr>
<td>Liver MDA (nmol/g. tissue)</td>
<td>0.39 &lt;0.05</td>
<td>0.45 &lt;0.01</td>
</tr>
<tr>
<td>Liver GPx activity (nmol of NADPH oxidized/min/mg)</td>
<td>-0.42 &lt;0.05</td>
<td>0.48 &lt;0.001</td>
</tr>
<tr>
<td>Hepatic CYP2E1 activities (nmol/min/mg protein)</td>
<td>--------</td>
<td>0.50 &lt;0.001</td>
</tr>
</tbody>
</table>

**Fig. 1:** RT-PCR of CYP2E1 expression

Lane M: 100 bp size DNA marker (Sigma);

Lanes 1-10 showed CYP2E1 bands (356bp) with different intensity and β-actin bands (790bp) which served as internal control.

Lanes: 1, 2, 4-6 and 10 represent group I.

Lanes 3 and 9: group II.

Lane 5: group III.

Lane 8: group IV.

**Fig. 2:** Comparison of CYP2E1 RT-PCR expression between the studied groups

P<0.001

P<0.01

P<0.01

13.4

22.9

17.7

14.2

G-I

G-II

G-III

G-IV
Fig. 3: Light microscopical photomicrograph of liver tissue of control group (A) showing the normal hepatocytes with rounded nuclei forming hepatic cell cords (→) radiating from the central vein (CV), liver tissue of diabetic rat (B) showing the hypertrophied and vacuolated hepatic cells and the heavy cellular infiltration (→) and (C) shows small areas of focal necrosis and vacuolated hepatocytes. Liver tissue of diabetic rat (D) treated with taurine, treated with melatonin (E) showing the apparently normal hepatic cells with few inflammatory cells around a blood vessel (→) (H&E. Mag. x 400).
DISCUSSION

Both human and experimental animal models of diabetes exhibit high oxidative stress due to persistent and chronic hyperglycemia which depletes the activity of free radical scavenging enzymes and thus promotes free radicals generation. In recent years, it has been shown that dietary supplementation with natural antioxidants attenuated the oxidative stress and diabetic state induced by STZ. (7,22)

In the present study, in STZ induced diabetic rats, decreased body weight and increased plasma glucose level were observed, neither melatonin nor taurine were able to prevent weight loss, but taurine has the capability to return plasma glucose to near normal level which may be due to diminished rate of renal gluconeogenesis(23), inhibition of oxidative stress(24) or due to the potentiation of the effects of insulin(25). These findings indicate that taurine is involved in distinct processes necessary for the control of glucose homeostasis. On the other hand, melatonin did not significantly prevent the development of hyperglycaemia in the STZ-induced diabetic rats similar to the results of other researchers. (26,27)

The present study revealed marked increases in serum triglycerides, total cholesterol and liver enzymes in STZ-induced diabetic rats, but treatment of the diabetic rats with either melatonin or taurine resulted in marked decrease in serum lipids and liver enzymes with more decrease in taurine treated group, which may be due to up-regulation of hepatic LDL receptor and/or through improving the binding of LDL to them. (28)

In the current study, elevated liver MDA levels in STZ induced diabetic rat was demonstrated, similar to previous studies. (29,30) The reduced MDA levels after melatonin or taurine treatment could be related to their direct anti-oxidant effects through their direct scavenging action. (23,31) It has been suggested that taurine stabilizes biomembranes and attenuate tissue lipid peroxidation. (32) Because lipids are substrates for lipid peroxidation, a decrement in serum triglyceride levels could be another contributing factor to the reduced MDA levels under melatonin or taurine treatment. (8)

In the current study the significant higher plasma AOPP levels reported in untreated diabetic rats came in agreement with those of Kalousova et al.(33) but upon melatonin or taurine treatment, AOPP formation could decrease and this came in accordance with the studies of Eskiocak et al. and Kilic, and Yildirim (34, 35)

The high level of lipid peroxidation marker, in the diabetic rats is a reflection of insufficiency of antioxidant defenses in combating ROS-mediated damage. (36) In this study, the hepatic GRx activity was decreased in the diabetic tissues which may be due to hyperglycemia, leading to glycation of antioxidant enzymes causing its inactivation. (10).

Furthermore, Andallu et al., (37) reported that the decreased activities of SOD, CAT and GPx in diabetic rats
could be due to increased utilization for scavenging free radicals. In the present study, taurine increased the hepatic GPx activity which came in accordance with Franconi et al., since cysteine is a precursor of taurine and GSH, taurine supplementation may cause enhancement in GSH levels by directing cysteine into the GSH synthesis pathway. Therefore, increased GSH levels after taurine treatment may play an additional role in decreasing oxidative stress, but melatonin has no significant effect and this came in accordance with the result of Oktem et al.

It was reported previously that PON1 activity was reduced in several situations associated with oxidative stress. In the present study, PON1 was significantly lowered in diabetic rats, which might be related to increased lipid peroxide levels and/or glycation of HDL which may increase its turnover and reduce its efficiency. Inoue et al. reported that there are some inhibitors against PON1 activity in circulating blood of diabetic patients such as glycosylated proteins. Reduced PON1 activity was suggested to play a role in the severity of coronary atherosclerosis, especially in diabetics, and low concentration and enzymatic activity of PON1 were thought to be independent predictors of cardiovascular events in diabetic patients.

In the present study, it was observed that taurine or melatonin supplementation increased serum PON1 activities in STZ induced diabetes in rats which came in agreement with Dirican et al., Tas et al., and El Mesallamy et al. Because lipid peroxidation products have been reported to inhibit PON1 activity, the reduced tissue MDA levels, which reflected an improvement in the oxidative–anti-oxidative balance, may be a contributing factor to the increased serum PON1 activities. This effect may be one of the antiatherosclerotic activities of taurine, so, taurine supplementation may be beneficial for diabetic patients with decreased PON1 activity to make them less susceptible to coronary heart diseases. However, further investigations on the effect of taurine supplementation in healthy and diabetic humans are needed to support this suggestion. Topsakal et al. reported that melatonin may play a role in increasing the reduced PON concentrations by improving the glucose metabolism and/or oxidative stress.

CYP2E1 is inducible in several patho-physiological states including diabetes and its expression parallels increased ROS production and oxidative stress in various tissues of STZ-induced diabetes rats. In the current study, both the hepatic CYP2E1 enzyme activity and gene expression, were increased in STZ-induced diabetic rats as compared with control and both were significantly correlated with the studied oxidative stress parameters and with β-Hydroxybutyrate.

The present study supported previous observations on the CYP2E1-dependent liver injury in STZ-induced diabetic rats. This link stems from the unusually high capacity of CYP2E1 to generate free radicals which are thought to result in lipid peroxidation and thus contribute
to liver disease.\textsuperscript{(49)} Diabetes is commonly associated with the development of nonalcoholic steatohepatitis. Therefore, it is possible that the increased expression of CYP2E1 can lead to liver disease in diabetics.\textsuperscript{(50)} Also, it has been suggested that the increased ketones and other small organic molecules in diabetes act as inducers of CYP2E1. Although the mechanism is not fully understood, it may be related to an enhanced rate of gene transcription.\textsuperscript{(51)}

The current study, further demonstrated that the production of CYP2E1 both gene expression and enzyme activity can be prevented not only by taurine but also by melatonin supplementation, which is less than that of taurine so, they can protect the liver from the hepatic injury induced by type I diabetes. In correlation with these, this study showed that elevated levels of ketone bodies (\(\beta\)-HB) by STZ are reduced by taurine more than melatonin supplementation, so that the suppression of ketone production can be one of the mechanisms of a reduction in CYP2E1 gene expression in diabetic rats. These results came in agreement with Yao \textit{et al.},\textsuperscript{(11)} who showed that taurine supplementation caused a significant decrease in plasma \(\beta\)-HB levels in diabetic rats compared with untreated diabetic animals. Also, they concluded that the diabetes-induced CYP2E1 expression was down regulated by taurine, and the amounts of reduction of enzyme activities in the liver and kidneys were approximately parallel to the reduction of plasma concentrations of \(\beta\)-HB in diabetic rats after taurine treatment. Furthermore, the exact mechanism of inhibition of diabetes-induced CYP2E1 elevation by taurine warrants further studies.

Finally in the present study, the hepatic protective role of melatonin and taurine in STZ-induced diabetic liver damage was established by normalization of hepatic histological picture upon treatment of STZ induced diabetes by either taurine or melatonin.

\section*{CONCLUSION}

Adverse hepatic events associated with Type I diabetes may be a result of enhanced CYP2E1 gene expression and enzyme activity which may be due to increased oxidative stress or \(\beta\)-Hydroxybutyrate activity. Taurine has the capabilities more than melatonin in protecting the liver from the hepatic injury induced by type I diabetes, by either reducing the oxidative stress, or restoring CYP2E1 activity and gene expression. Therefore antioxidants might prove beneficial as an adjuvant treatment to insulin in type I diabetes associated with manifestations of liver injury.

\section*{Acknowledgements}

The authors thank Dr Abdel Razek Sheta, Department of Anatomy, Faculty Of Medicine, Tanta University, Egypt, for his performance of the histopathology of the liver samples.

\section*{REFERENCES}


14. McGarry JD, Guest MJ and Foster DW (1970): Ketone body metabolism in the ketosis of


مقارنة التأثير الوقائي للثورين و الميلاتونين على سيتوكروم ب 0.5/1 و بعض دلالات الأكمة في نموذج مرض البوال السكري المحدث تجريبياً في الفئران باستخدام ستريبوريسين

مثال البطن، عزة حسن*، هبة عبد الحليم**

أقسام الكيمياء الحيوية الطبية، الميكروبيولوجى، المناعة، الفارماكولوجى*
كلية الطب، جامعة طنطا، كلية الطب، تجربة محددة للسكري في بوامرض ضد الميلاتونين و الثورين المحتملة وقائية ستربتوزوسين باستخدام الفئران البطن من مصانع طنطا الجلوبية الكيمياء، أقسام المناعة والميكروبيولوجى، الفارماكولوجى، طنطا الجلوبية الطبية، كلية الطب

صممت هذه الدراسة لتعزيز الوقاية المحتملة للثورين والميلاتونين ضد مرض البوال السكري المحدث تجريبياً في الفئران باستخدام ستريبوريسين و قد أجريت هذه الدراسة على قرن الثورين البائية التي قسمت إلى (مجموعة غير مضافة 24 مصابة بالبوال السكري و تم إعطائها ميلاتونين (400 ميكروجم/كم/ساعة). مجموعه مصابة بالبوال السكري و تم إعطائها ثورين (2% في مياه الشرب) وفي نهاية فترة الدراسة تم الاختبار．

جمع عينات الدم لتحديد مستوي الجلوکوز - الكولسترول الكلي - تليلي والكيراتينات - انزيمات الكبد - تليلي، و مستويات الأكسدة - انزيمات الثيوپربوتوكسين - نشاط ببتيد جلوکوز ترتر فورميتك - و وترین (500 ب 2-1)

دراسة هيستوپاتولوجية للسنسج الكبدى

و بعد انتهاء عدة التجربة (30 يوم) أسفرت النتائج على أن هناك ارتفاع في نشاط الجلوکوز بالبوال السكري ب 0.5/1، أيضاً تعبير جيني و كان هذا الارتفاع متلازماً مع تغير ذو دلالة إحصائية في وترین فورميتك في البوال السكري مما يدل على اتخاذ إصابات بالكبد

كما وجد أن اعطاء كلا من الميلاتونين و الثورين للقرن الأكسدة بالبوال السكري قد أثر بنفعية في تقليل هذه الدلالات ولكن كنا تأثير الثورين هو الأفضل إحصائياً بالمقارنة بتأثير الميلاتونين كما وجد أن قطرة الثورين على عينات سنسجية وتروتوكتسيس (ب) يمكن أن يؤدی إلى تقليل نشاط ببتيد جلوکوز ترتر فورميتك وتقليل نسبة الإصابة بالكبد.

الاستنتاج أن اعطاء الثورين أدى إلى تأثير أفضل من أثر الميلاتونين في تقليل دلالات الأكمة و تقليل نشاط ببتيد جلوکوز ترتر فورميتك و تقليل نسبة الإصابة بالكبد. ومن الملاحظ أيضاً تعبير الجين و كذلك أدى إلى تسليم متوسط ببتيد الكبد من كلا الببتيدات في البوال السكري. هذا فإن مضادات الأكمة قد تكون صحة مساعدة في علاج النوع الأول لمرض البوال السكري مما يؤدي إلى تحسن اعراض الإصابة الكبدية المصاحبة له.